
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Anticancer Drugs From Zeneca in Regulatory Phase of Development
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogen agent, has received approval for marketing in the United Kingdom for the treatment of advanced prostate cancer. Zeneca has also filed for approval of Casodex in the United States and several other countries, Zeneca president Robert C. Black said at a media briefing.
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogenagent, has received approval for marketing in the United Kingdomfor the treatment of advanced prostate cancer. Zeneca has alsofiled for approval of Casodex in the United States and severalother countries, Zeneca president Robert C. Black said at a mediabriefing.
Other new anticancer agents from Zeneca in clinical developmentinclude Tomudex, a cytotoxic thymidylate synthase inhibitor forcolorectal cancer, and Arimidex, an oral nonsteroidal aromataseinhibitor for breast cancer.
The company's LHRH agonist analog Zoladex (goserelin acetate),currently marketed as a 3.6 mg implant for prostate cancer, hasbeen recommended for a new indication--palliation of advancedbreast cancer . An NDA has also been filed for a 10.8-mg, 3-monthdepo formulation, Mr. Black said.
Articles in this issue
about 31 years ago
First Results of Avicidin Trialsabout 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesabout 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicabout 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationabout 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseabout 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialabout 31 years ago
Ultrasound Breast Screens Useful in Selected Womenabout 31 years ago
New Roles Forecast for Endocrine Therapyabout 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsabout 31 years ago
Osteosarcoma Chemo Regimens DebatedNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































